ES2094733T3 - Deteccion de enfermedades o disfunciones neurologicas. - Google Patents

Deteccion de enfermedades o disfunciones neurologicas.

Info

Publication number
ES2094733T3
ES2094733T3 ES89313410T ES89313410T ES2094733T3 ES 2094733 T3 ES2094733 T3 ES 2094733T3 ES 89313410 T ES89313410 T ES 89313410T ES 89313410 T ES89313410 T ES 89313410T ES 2094733 T3 ES2094733 T3 ES 2094733T3
Authority
ES
Spain
Prior art keywords
detection
neurological
nptp
diseases
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89313410T
Other languages
English (en)
Inventor
Jack R Wands
Jerome Gross
Mehmet Ozturk
La Monte Suzanne De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2094733T3 publication Critical patent/ES2094733T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Abstract

LA DETECCION Y DIAGNOSIS DE ENFERMEDAD O DISFUNCION NEUROLOGICA USA ANTICUERPOS CONTRA UNA FORMA NEUROLOGICA DE PROTEINA DE FIBRA PANCREATICA (NPTP). ESPECIFICAMENTE, LA ENFERMEDAD DE ALZHEIMER, EL SINDROME DE DOWN Y OTRAS ENFERMEDADES O DISFUNCIONES NEUROLOGICAS SE DIAGNOSTICAN USANDO ANTICUERPOS MONOCLONALES PARA DETECTAR EL NPTP. SE DIFUNDE IGUALMENTE NPTP SUSTANCIALMENTE PURO PUES ES UN METODO DE DIAGNOSTICO DE ENFERMEDAD PANCREATICA USANDO ANTICUERPOS CONTRA LA PROTEINA DE FIBRA PANCREATICA.
ES89313410T 1988-12-21 1989-12-21 Deteccion de enfermedades o disfunciones neurologicas. Expired - Lifetime ES2094733T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28720788A 1988-12-21 1988-12-21
US45197589A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
ES2094733T3 true ES2094733T3 (es) 1997-02-01

Family

ID=26964334

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89313410T Expired - Lifetime ES2094733T3 (es) 1988-12-21 1989-12-21 Deteccion de enfermedades o disfunciones neurologicas.

Country Status (10)

Country Link
US (1) US6071705A (es)
EP (1) EP0378924B1 (es)
JP (1) JP3309972B2 (es)
AT (1) ATE145285T1 (es)
AU (3) AU4837990A (es)
CA (1) CA2006332C (es)
DE (1) DE68927459T2 (es)
ES (1) ES2094733T3 (es)
GR (1) GR3022287T3 (es)
WO (1) WO1990006993A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
JP3513859B2 (ja) * 1993-04-20 2004-03-31 ザ・ジェネラル・ホスピタル・コーポレーション 神経糸状タンパク質遺伝子発現およびアルツハイマー病の検出
US20030033621A1 (en) * 1997-02-26 2003-02-13 De La Monte Suzanne Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
JP4194664B2 (ja) 1997-02-26 2008-12-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置または予防のために効果的な薬物をスクリーニングするためのトランスジェニック動物および細胞株
US6342350B1 (en) 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
GB9719796D0 (en) * 1997-09-17 1997-11-19 Medical Res Council Medicament
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
ATE374619T1 (de) * 2001-03-08 2007-10-15 Nymox Pharmaceutical Corp Verwendung von neurofilamentproteinen zur behandlung von tumoren
EP1387698B1 (en) * 2001-05-04 2007-11-14 Nymox Corporation Method of preventing cell death using antibodies to neural thread proteins
DE60224231D1 (de) * 2001-05-16 2008-01-31 Nymox Corp Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen
NZ529911A (en) * 2001-05-25 2008-05-30 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
KR100966232B1 (ko) * 2001-07-19 2010-06-25 니목스 코포레이션 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US20050266099A1 (en) * 2002-04-25 2005-12-01 Alon Shalev Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
GB0223187D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Screen
JP2006515999A (ja) * 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
DE602004022645D1 (de) * 2003-03-31 2009-10-01 Univ Florida Beurteilung von nervenschäden anhand von blutproben
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US7943046B2 (en) * 2004-10-01 2011-05-17 Agilent Technologies, Inc Methods and systems for on-column protein delipidation
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
ATE514950T1 (de) 2007-09-07 2011-07-15 Univ Zuerich Verfahren zur untersuchung von sepsis bei menschen
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4816388A (en) * 1985-10-30 1989-03-28 Children's Medical Center Corporation Human prealbumin and related methods and products
FR2661187B1 (fr) * 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.

Also Published As

Publication number Publication date
ATE145285T1 (de) 1996-11-15
JPH04502364A (ja) 1992-04-23
AU641376B2 (en) 1993-09-23
DE68927459T2 (de) 1997-04-24
WO1990006993A1 (en) 1990-06-28
EP0378924A3 (en) 1991-11-06
AU5265393A (en) 1994-03-17
GR3022287T3 (en) 1997-04-30
US6071705A (en) 2000-06-06
EP0378924A2 (en) 1990-07-25
CA2006332C (en) 2003-04-08
AU4837990A (en) 1990-07-10
JP3309972B2 (ja) 2002-07-29
EP0378924B1 (en) 1996-11-13
CA2006332A1 (en) 1990-06-21
DE68927459D1 (de) 1996-12-19

Similar Documents

Publication Publication Date Title
ES2094733T3 (es) Deteccion de enfermedades o disfunciones neurologicas.
DE69633973D1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
ATE114672T1 (de) Peptidzusammensetzung und verfahren zum nachweis von antikörpern gegen htlv-iii.
NO972024L (no) Metoder for diagnostisering av glaukom
DK0542255T3 (da) Monoklont antistof, der genkender C-terminus i hBNP
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
EP0261224A4 (en) SYNTHETIC HTLV III PEPTIDE COMPOSITIONS AND THEIR USE.
DE69127487T2 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE3879085T2 (de) Snrnp-a-antigen und fragmente davon.
FI922666A0 (fi) Diagnostiskt foerfarande.
DE3587542T2 (de) Verfahren zur Diagnose in vitro von menschlichen Cytomegalovirusinfektionen und Anwendung von monoklonalen Antikörpern gegen Cytomegaloviren, die mit einer cytomegalovirusinduzierten Proteinkinase reagieren.
ATE104355T1 (de) Nachweis eines mit atmungskrankheiten verbundenen einzelstammes von chlamydia.
ATE154395T1 (de) Monoklonale antikörper
ATE86261T1 (de) Tumorassoziiertes antigen.
KR880701886A (ko) 췌장효소원의 유리활성화 펩티드의 면역검정에 의한 질병의 진단, 위중도 예견, 및 모니터링
RU95101284A (ru) Способ диагностики инфаркта кишечника
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis
ATE146597T1 (de) Verfahren zur diagnose von hiv-infektionen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 378924

Country of ref document: ES